Phase 3 Study of the Efficacy and Safety of MR Arthrography Using the NEMO-103 Injection in Patients With Known or Suspected Shoulder Joint Diseases

Exclusion Criteria

• •1. Subjects with contraindications to MRI
• •2. Subjects expected to be clinically unstable during the study
• •3. Subjects who have received or used another IP or investigational device within 4 weeks or ≥5 half-lives, whichever is longer, prior to informed consent.
• •4. Pregnant or breast-feeding women, or women of childbearing potential and men who do not agree to use appropriate methods of contraception during the study.
• •5. Determined to be ineligible to participate in the study by the investigator due to any other reasons.